Scarica l'app Stockscreener
27.86
5.53%
1.46
Dopo l'orario di chiusura:
27.04
-0.82
-2.94%
Oruka Therapeutics Inc Borsa (ORKA) Ultime notizie
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Does UBS’s New Coverage Reframe Oruka Therapeutics (ORKA) as a Peptide Platform, Not Just a Biotech? - Sahm
How buybacks impact Oruka Therapeutics Inc. stock valueJuly 2025 Macro Moves & Risk Controlled Swing Alerts - ulpravda.ru
Can Oruka Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Trade Ideas & Reliable Breakout Stock Forecasts - ulpravda.ru
Will Oruka Therapeutics Inc. (HQ1) stock top growth indexes2025 Market WrapUp & Precise Swing Trade Entry Alerts - ulpravda.ru
Why Oruka Therapeutics Inc. stock is a must watch in 2025Earnings Beat & AI Powered Market Entry Strategies - ulpravda.ru
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyJuly 2025 Technicals & Reliable Price Breakout Alerts - ulpravda.ru
Aug Outlook: Why Oruka Therapeutics Inc. stock is favored by top institutions2025 Retail Activity & Real-Time Volume Spike Alerts - ulpravda.ru
What sentiment indicators say about Oruka Therapeutics Inc. stockJuly 2025 Institutional & Technical Buy Zone Confirmations - ulpravda.ru
Is Oruka Therapeutics Inc. stock a dividend growth opportunity - ulpravda.ru
Dental EconomicsOruka Therapeutics, Inc.Common Stock (Nasdaq:ORKA) Detailed Stock Data - FinancialContent
UBS initiates coverage of Oruka Therapeutics (ORKA) with buy recommendation - MSN
Oruka Therapeutics stock initiated with Buy rating at UBS on cancer drug potential - Investing.com Canada
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears - Seeking Alpha
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 8.3%What's Next? - MarketBeat
Oruka Therapeutics Builds Oncology Programs at Molecular Level - Kalkine Media
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka T - GuruFocus
Oruka Therapeutics COO Sandler sells $370,795 in shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Sandler sells $370,795 in shares - Investing.com UK
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3%Should You Buy? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.3%Time to Sell? - MarketBeat
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) and Oruka Therapeutics (NASDAQ:ORKA) Financial Survey - Defense World
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin - Sahm
Oruka Therapeutics stock hits 52-week high at 32.31 USD By Investing.com - Investing.com Australia
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com India
Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $214,270.00 in Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 11.3%Here's What Happened - MarketBeat
Piper Sandler Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
How Oruka Therapeutics Inc. stock compares to growth peersWeekly Gains Report & AI Based Buy and Sell Signals - Улправда
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors - TipRanks
Oruka Therapeutics Earnings Notes - Trefis
Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors By Investing.com - Investing.com India
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors - Investing.com
Oruka Therapeutics Appoints Christopher Martin to Board - TipRanks
Oruka Therapeutics Announces New Board Member and Board Transition - The Manila Times
B Group Inc. Increases Position in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics (ORKA) Stock Analysis Report | Financials & Insights - Benzinga
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Geode Capital Management LLC - Defense World
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Affinity Asset Advisors LLC - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics stock hits 52-week high, reaching $31.01 By Investing.com - Investing.com Nigeria
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):